SCHEMBL5653173

SCHEMBL5653173

COc1cc(/C=C/C(=O)c2ccc(O)cc2)cc(OC)c1OC

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KRAS P01116 6/20 0.79
CA1 P00915 4/20 0.79
CA2 P00918 4/20 0.79
ALDH1A1 P00352 2/20 0.77
SMN1; SMN2 Q16637 2/20 0.77
ATM Q13315 1/20 0.77
L3MBTL1 Q9Y468 1/20 0.77
ABCG2 Q9UNQ0 4/20 0.75
CYP1A1 P04798 1/20 0.72
CYP1A2 P05177 1/20 0.72
CYP2C8 P10632 1/20 0.72
CYP2D6 P10635 1/20 0.72
CYP1B1 Q16678 1/20 0.72
ABCB1 P08183 2/20 0.72
KDM4E B2RXH2 1/20 0.70
LMNA P02545 1/20 0.70
MAPT P10636 1/20 0.70
MEN1 O00255 1/20 0.69
KMT2A Q03164 1/20 0.69
BACE1 P56817 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5653179 1.00 KRAS (0.79) KRASCA1CA2ALDH1A1SMN1; SMN2
SCHEMBL6780730 0.88 ABCG2 (0.88) KRASABCG2ABCB1BACE1TUBB4A
SCHEMBL6780724 0.88 ABCG2 (0.88) KRASABCG2ABCB1BACE1TUBB4A
SCHEMBL615818 0.88 KRAS (1.00) KRASCA1CA2ALDH1A1SMN1; SMN2
SCHEMBL13018515 0.88 CA1 (1.00) KRASCA1CA2ALDH1A1SMN1; SMN2
SCHEMBL13018517 0.88 KRAS (1.00) KRASCA1CA2ALDH1A1SMN1; SMN2
SCHEMBL19183065 0.88 CA1 (1.00) KRASCA1CA2ALDH1A1SMN1; SMN2
SCHEMBL31374858 0.87 KRAS (1.00) KRASCA1CA2ALDH1A1SMN1; SMN2
SCHEMBL2448676 0.87 KRAS (1.00) KRASCA1CA2ALDH1A1SMN1; SMN2
SCHEMBL2448671 0.87 KRAS (1.00) KRASCA1CA2ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7279470-B2 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2007-10-09 US disclosed
US-7067517-B2 Use of compounds for decreasing activity of hormone-sensitive lipase NERO NORDISK A/S (DK) 2006-06-27 US disclosed
EP-1458374-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP disclosed
EP-1458375-A2 COMPOSITIONS FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP disclosed
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
WO-2003051842-A2 COMPOSITIONS DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO disclosed
WO-2003051841-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO disclosed
US-5525457-A Copolymers of unsaturated carboxylic acid, an epoxy-functional monomer, and cinnamoylphenyl group-monomer; high halation preventing effect, involves no sublimation of radiation absorbing components contained therein, possesses excellent heat resistance, dry etching performance, storage stability JAPAN SYNTHETIC RUBBER CO., LTD. (JP) 1996-06-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase LIPE, PNLIP, LPL KRAS 4635/4885CA1 3261/4885CA2 3744/4885
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive LIPE, PNLIP, LPL KRAS 4717/4885CA1 2368/4885CA2 2834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.